Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
JANUVIA (sitagliptin) is an oral small-molecule DPP-4 inhibitor approved in 2006 for type 2 diabetes management. It works by increasing incretin hormone levels to stimulate insulin secretion in response to glucose elevation. The drug is typically used as monotherapy or in combination with other antidiabetic agents.
Mature franchise nearing patent cliff (0.7 years to LOE); brand team focus shifting to lifecycle extension and managed decline strategy.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy Subjects
Semaglutide vs Sitagliptin
Worked on JANUVIA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
$4.1B Medicare spend — this is a commercially significant brand
JANUVIA supports 981 linked roles across manufacturing, QA, medical affairs, and R&D functions at Merck, reflecting a fully-integrated, mature commercial infrastructure. Career paths are stable but increasingly focused on operational efficiency and transition planning rather than growth-phase innovation.
981 open roles linked to this drug